Cancer experts from around the country will gather in Albany in October for a two-day multidisciplinary gathering of academic and community-based care providers and researchers for a conference designed to support practical recommendations for clinical practice and cancer research that improves patient care.
The 7th Annual Translational Oncology Research Symposium will be held Oct. 3-4 at the Hilton Garden Inn Albany Medical Center. A focus of the 2013 conference will be musculoskeletal tumors and cancers of the breast, genitourinary system, liver and lungs.
The symposium is hosted by Albany Medical College and New York Oncology Hematology, P.C. (NYOH), and is jointly sponsored by the Medical College of Wisconsin. Attendees can earn AMA PRA Category 1 Credits ™ by participating in this continuing medical educational activity.
Among the highlights will be discussion of how breakthroughs in diagnostic and predictive tools are paving the way for individualization of cancer treatment.
“The advent of personalized oncology has fostered a ‘next generation of pathology’ focused on predictive biomarkers,’’ said Jeffrey S. Ross, MD, chairman of Albany Med’s Department of Pathology and Laboratory Medicine and a keynote address speaker. “This year’s Translational Oncology Symposium is replete with descriptions of genomic markers that predict both benefit and resistance for both conventional and modern targeted therapies for cancer.” There is no fee for this symposium. For more information or to register, visit www.TransOncNY.org.